Relmada Therapeutics (RLMD) Stock Forecast & Price Target

$2.80 +0.05 (+1.82%)

(As of 11/22/2024 ET)

Relmada Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 2 Analyst Ratings

Sell
1

Hold
0

Buy
1

Based on 2 Wall Street analysts who have issued ratings for Relmada Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a buy rating for RLMD.

Consensus Price Target

$7.50
167.86% Upside

According to the 2 analysts' twelve-month price targets for Relmada Therapeutics, the average price target is $7.50. The highest price target for RLMD is $13.00, while the lowest price target for RLMD is $2.00. The average price target represents a forecasted upside of 167.86% from the current price of $2.80.

Get the Latest News and Ratings for RLMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Relmada Therapeutics and its competitors.

RLMD Analyst Ratings Over Time

Type	Current Forecast 11/24/23 to 11/23/24	1 Month Ago 10/25/23 to 10/24/24	3 Months Ago 8/26/23 to 8/25/24	1 Year Ago 11/24/22 to 11/24/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.50	$7.50	$2.00	$13.00
Forecasted Upside	167.86% Upside	106.61% Upside	-27.80% Downside	348.28% Upside
Consensus Rating	Hold	Hold	Sell	Buy

“This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!

RLMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RLMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Relmada Therapeutics Stock vs. The Competition

Type	Relmada Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	167.86% Upside	27,098.21% Upside	7.66% Upside
News Sentiment Rating	Neutral News See Recent RLMD News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Jefferies Financial Group 2 of 5 stars	Upgrade	Hold ➝ Buy	$3.50 ➝ $13.00	+329.04%
6/5/2024	The Goldman Sachs Group 2 of 5 stars	Downgrade	Neutral ➝ Sell	$3.00 ➝ $2.00	-32.20%
8/10/2023	Mizuho 2 of 5 stars	Lower Target		$26.00 ➝ $25.00	+819.11%
1/23/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform	$42.00 ➝ $10.00	+126.24%
12/8/2022	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$7.00 ➝ $4.00	-3.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:54 PM ET.

RLMD Forecast - Frequently Asked Questions

: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Relmada Therapeutics is $7.50, with a high forecast of $13.00 and a low forecast of $2.00.
: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last twelve months. There is currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RLMD, but not buy additional shares or sell existing shares.
: According to analysts, Relmada Therapeutics's stock has a predicted upside of 167.86% based on their 12-month stock forecasts.
: Over the previous 90 days, Relmada Therapeutics's stock had 1 upgrade by analysts.
: Relmada Therapeutics has been rated by research analysts at Jefferies Financial Group in the past 90 days.
: Analysts like Relmada Therapeutics less than other "medical" companies. The consensus rating for Relmada Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RLMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

This page (NASDAQ:RLMD) was last updated on 11/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Stock Forecast & Price Target